Value Assessment of Technology: The Pharmacotherapy Outcomes Research Center, College of Pharmacy

Diana Brixner, PhD, RPh
diana.brixner@utah.edu
Professor and Chair, Department of Pharmacotherapy
Executive Director, Pharmacotherapy Outcomes Research Center
University of Utah College of Pharmacy
2007-2008 President, International Society of Pharmacoeconomics and Outcomes Research (http://www.ispor.org)
2009-2011 Board of Directors, Academy of Managed Care Pharmacy

Agenda

• Background on Effectiveness Research
• The Pharmacotherapy Outcomes Research Center
• Case Studies
  • Evaluation of exenatide in national EMR database
  • Utah Medicaid Exclusivity Analysis in Statins
  • Down Syndrome Research Plan
  • Other ongoing research programs
• Summary

National Health Expenditures per Capita and Their Share of Gross Domestic Product, 1960-2008

Per Capita Total Current Health Care Expenditures, U.S. and Selected Countries, 2008

Note: Amounts in U.S.$ Purchasing Power Parity, see www.oecd.org/std/ppp. Includes only countries over $2,500. OECD defines Total Current Expenditures on Health as the sum of expenditures on personal health care, preventive and public health services, and health administration and health insurance; it excludes investment.

Deaths per 100,000 population*

* Countries' age-standardized death rates before age 75; including ischemic heart disease, diabetes, stroke, and bacterial infections.

See report Appendix B for list of all conditions considered amenable to health care in the analysis.

Data: E. Nolte and C. M. McKee, London School of Hygiene and Tropical Medicine analysis of World Health Organization mortality files (Nolte and McKee 2008).

Mortality Amenable to Health Care

Source: Commonwealth Fund National Scorecard on U.S. Health System Performance, 2008

Infant Mortality Rate


Infant deaths per 1,000 live births

International Comparison, 2004

Source: Commonwealth Fund National Scorecard on U.S. Health System Performance, 2008

Healthy Life Expectancy at Age 60, 2002

Developed by the World Health Organization, healthy life expectancy is based on life expectancy adjusted for time spent in poor health due to disease and/or injury

Note: Indicator was not updated due to lack of data. Baseline figures are presented.


When you spend more than you have ....

• Where the expenditure on health grows faster than the national health budget, there are 3 reactions possible.

1. Increase funding sources
2. Improve system functioning for better efficiency
3. Ration public financing of medical services

• There are various examples in countries around the world where each one of these approaches are used differently.

• The United States has defined their approach as “Healthcare Reform.”

Source: Commonwealth Fund National Scorecard on U.S. Health System Performance, 2008
U.S. Healthcare Reform Goals

• To deliver near-universal access to U.S. citizens.
• To identify funding and savings as an additional goal of the healthcare reform initiative.
• To create a system that is sustainable over the long term.
• In order to do so, payment reform as well as an emphasis upon quality, efficiency, wellness, and prevention will be required.

Defining Value in Healthcare

Comparative Effectiveness

• The generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition or to improve the delivery of care.
• The purpose of CER is to assist consumers, clinicians, purchasers, and policy makers to make informed decisions that will improve health care at both the individual and population levels.

Patient Centered Outcomes Research Institute (PCORI); an independent, non-profit organization

• A project agenda based on the burden of diseases in the U.S., particularly chronic conditions.
• Primary research and systematic reviews of existing studies.
• Research conducted for the institute will be peer reviewed and made available to the medical community and general public.
• AHRQ is authorized to take proactive steps to disseminate the findings to physicians, health care providers, patients, insurance providers, and health care technology vendors.
• The bill also calls for AHRQ to award grants for training in the research methods used by the institute.

Key Issues for Private and Public Payers

• Healthcare is getting too expensive
• We need to prioritize
  • Step 1: Do not pay for treatments which do not deliver value
  • Step 2: Define Value: How much do we pay for what we get?

VALUE = Cost / Outcome
Value is Comparative

The perceived value of a product to a customer is based on...

\[ V = R \pm D \]

Positive differential Value?

Negative differential Value?

Source: PriceSpective

Efficacy / Effectiveness

- Efficacy
  - RCT
  - High internal validity
  - Limited generalizability

- Effectiveness
  - Observational studies
  - High external validity
  - Lack of Controls

Payers Want Information Beyond RCTs...

Efficacy and safety in a small population with a restricted study protocol

RCT Randomized Clinical Trials

GAP Decision makers need real world information to make health care decisions for large populations within defined budgets

Patient Population

Real World Data

Answering Basic Questions

ISPOR Real World Task Force Draft, July 25, 2006

RCTs

CLINICAL GUIDELINES

CONDITIONAL COVERAGE

Drummond et al., IJTAHC, June, 2008
What Are Health Outcomes?

“Outcomes beyond safety and efficacy which capture the psychological, social, physical, functional and economic impact of disease and treatment for the individual and society.”

Identifying Health Related Outcomes

• Economic outcome
  • Hospitalizations avoided
  • Worker productivity

• Clinical outcome
  – Clinical efficacy/effectiveness – cure rate
  – Relief / reduction in symptoms
  – Decreased/increased incidence of morbidity
  – Mortality

Identifying Health Related Outcomes

• Humanistic outcome:
  • Health Related Quality of Life (QoL)
  • Patient satisfaction and compliance
  • Ability to perform activities

• Challenges:
  • Identifying relevant outcomes
  • Valuing outcomes

Costs to Consider for Drugs

• Drug Acquisition Costs
• Preparation Costs
• Offset of Medical Costs
• Cost of Adverse Events
• Cost of Treatment Failures
• All are components of true drug cost
When is Economic Evaluation Necessary?

Drug A relative to the alternative B

<table>
<thead>
<tr>
<th>Drug A: More Effective</th>
<th>Drug A: Less Effective</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE Study necessary</td>
<td>Drug A – Optimal Strategy: Study not necessary</td>
</tr>
<tr>
<td>Drug B is Optimal Choice: PE Study not necessary</td>
<td>PE Study necessary</td>
</tr>
</tbody>
</table>

US Health Technology Assessment Examples

- Blue Cross Blue Shield Technology Evaluation Center (TEC)
- Wellpoint Comparative Effectiveness Guidelines
- AMCP’s Format for Formulary Submissions
- Oregon’s Drug Effectiveness Review Project (DERP)
- Agency of Healthcare Policy & Research (AHRQ)
  - Evidence Based Practice Centers (EPCs)
  - Centers for Education and Research on Therapeutics (CERTs)
  - Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) Program
  - Comparative Effectiveness Reports

Utilization of the AMCP Format

- >150 million members in health plans are exposed to the AMCP Format.
- Health plans are in different stages of AMCP Format implementation
- Wide acceptance by pharmaceutical companies – building Dossiers into overall development and reimbursement planning
- Similar submission requirements in other countries – Great Britain, Australia, Canada, other countries

Who is Using Real World Data?

- Germany
  - Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
    - RCTS for clinical evidence
    - Less reliance on modeling
- Australia
  - Pharmaceutical Benefits Advisory Committee (PBAC)
    - Clinical evidence for approval
    - Clinical evidence for reimbursement
Who is Using Real World Data?

- **United Kingdom**
  - National Institute for Clinical Effectiveness (NICE)
    - Clinical evidence
    - Modeling for real world effectiveness
- **Canada**
  - Canadian Agency for Drugs and Technologies in Health (CADTH)
    - Canadian Drug Review (CDR) process

Who is Using Real World Data?

- **United States**
  - Medicare Modernization Act (MMA) 2003
    - Section 1013
  - Agency of Healthcare Policy & Research (AHRQ)
    - Comparative clinical effectiveness
    - Appropriateness of health care
  - Academy of Managed Care Pharmacy (AMCP)
    - Format Dossiers

Pharmacotherapy Outcomes Research Center

**Mission:**

Design, conduct and communicate outcomes research studies to demonstrate the value of new technologies in the treatment of disease

Center Objectives

- Define the research question to define “value”
- Work with payer organization or sponsor in the design of research projects and selection of appropriate database to answer the question
- Publish study results through professional meetings and peer-reviewed publications
PORC’s Skills Base

- Health economics
- Modeling
- Various clinical subspecialties
- Drug information (pharmacoepidemiology)
- Statistical analysis
- Programming
- Psychometrics
- Database management
- Internationally recognized in Outcomes Research and Health Technology Assessment

Data Base Expertise

- PORC has research experience and access to numerous secondary datasets
  - Commercial claims
  - Medicaid claims
  - Electronic medical record (EMR)

- Core competencies in multiple database types enables PORC to utilize the most appropriate data to address outcomes research questions in the target population
Data Base Expertise

- National Commercial Insurance Claims
- U.S. and Utah Medicaid claims
- Electronic medical record (EMR); national and regional
- Medicare (Part A&B)
- UUHC Enterprise Datawarehouse
  - Community Clinics (EPIC)
  - Cerner (Inpatient; hospital clinics)
  - UPDB
- Government Supported Databases
  - NHANES
  - NAMCS

Key Accomplishments 2007-2010

- 2005 - 2010 Publications
  - Published: 113
  - Posters: 154
  - Invited Presentations: 66
- M.S. program 5
- Graduated fellows 9
- Visiting faculty program on going
- PhD Program approved in 2010 in Pharmacotherapy Outcomes and Health Policy
- Total Dollars in research grants since 2004 11.4 Million

University Based Research

- Oncology
  - Resource Use and Cost across 7 different cancers using EDW and UPDB.
  - Evaluation or radiation therapy in bone metastasis of breast and prostate cancer.
- Sarcopenia
  - Development of predictive model based on NHANES.
  - Validation in Community Clinic patients.
- Orthopedics
  - Evaluation of anesthesiology techniques in pain management.
- Physical Therapy
  - Assessment of outcomes and cost in back pain management.
- Community Clinic Research
  - Assessment of diabetes intervention programs by pharmacists in the Community Clinics.
- UU Brain Institute
  - Collaboration on assessment of QoL in Down Syndrome Patients

Case Studies
Study Population

- EMR Population Jan 1, 2000 to June 30, 2007; N = 7,935,736
- T2DM population ≥18 years and older; n = 564,170 (7.1%)
- Eligible patients after exenatide prescription inclusion; n = 12,745 (2.3%)
- Eligible patients after continuous activity applied; n = 5,961 (46.8%) (≥395 days pre and 6 month post index date)
- Eligible patients with data for at least one outcome measure pair; n = 4,823 (80.9%)
- Eligible patients after treatment medication identified; n = 2,086 (43.3%)

Characteristics of Study Population

<table>
<thead>
<tr>
<th>Age</th>
<th>&lt;40</th>
<th>40-64</th>
<th>≥65</th>
</tr>
</thead>
<tbody>
<tr>
<td>mean age 55.9 years (10.7sd)</td>
<td>146</td>
<td>1482</td>
<td>458</td>
</tr>
<tr>
<td>Gender</td>
<td>Male</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td></td>
<td>885</td>
<td>8525</td>
<td>80</td>
</tr>
<tr>
<td>Race</td>
<td>Caucasian</td>
<td>Black</td>
<td>Hispanic</td>
</tr>
<tr>
<td></td>
<td>928</td>
<td>394</td>
<td>20</td>
</tr>
<tr>
<td>Region</td>
<td>Northeast</td>
<td>Southeast</td>
<td>Midwest</td>
</tr>
<tr>
<td></td>
<td>384</td>
<td>928</td>
<td>618</td>
</tr>
<tr>
<td>Clinical Characteristics</td>
<td>Mean A1C (%)</td>
<td>Mean BMI (kg/m²)</td>
<td>Mean Weight (lbs)</td>
</tr>
<tr>
<td></td>
<td>8.5</td>
<td>38.5</td>
<td>243.4</td>
</tr>
</tbody>
</table>
**Percent Change in A1C After Exenatide Initiation**

![Graph showing percent change in A1C](image)

- **Baseline A1C (%)**
  - Total: 8.4
  - MET: 8.2
  - SU: 8.5
  - TZD: 8.2
  - MET + SU: 8.5
  - MET + TZD: 8.2
  - MET + SU + TZD: 8.5

- **A1C Change from Baseline (%)**
  - Total: -0.70
  - MET: -0.93
  - SU: -1.04
  - TZD: -0.82
  - MET + SU: -0.72
  - MET + TZD: -0.63
  - MET + SU + TZD: -0.52

**Notes:**
- *p<0.001
- †p=0.003
- **6 months ± 45 days

---

**BMI (kg/m²) Change After Exenatide Initiation**

![Graph showing BMI change](image)

- **Baseline BMI (kg/m²)**
  - Total: 38.5
  - MET: 39.5
  - SU: 37.1
  - TZD: 37.0
  - MET + SU: 38.0
  - MET + TZD: 38.1
  - MET + SU + TZD: 38.5

- **BMI change (kg/m²)**
  - Total: -0.34
  - MET: -0.86
  - SU: -0.29
  - TZD: -0.02
  - MET + SU: -1.02
  - MET + TZD: -1.12
  - MET + SU + TZD: -1.07

**Notes:**
- *p<0.001
- †p=0.128
- ‡p=0.003
- **6 months ± 45 days

---

**Conclusions**

- Average baseline A1C (8.5%) and BMI (38.5 kg/m²) was high in this T2DM population.
  - It is difficult for T2DM patients to achieve A1C and body weight goals in the real world.
- Exenatide therapy over 6 months demonstrated significant reductions in A1C, weight and BMI.
  - Results were consistent with clinical trial data.
- Use of concomitant medications decreased when exenatide was added.
Documentation of Pharmacy Cost

Pharmacy Cost in the Preparation of Chemotherapy Infusions

- Determine key components of pharmacy-related costs in preparation of chemotherapy infusions
- Project data from four centers to national insurance claims database
- Describe implications of resources and costs on reimbursement policy under MMA of 2003


Survey: Fixed-Cost Analysis

Key Cost Variables
- Drug Storage
- Space Rental
- Inventory Management
- Insurance Management
- Waste Management
  - Payroll
  - Equipment
  - Supplies
  - Shipping
- Information Resources

Fixed Cost Survey
- Annualized pharmacy-related production costs
- No purchasing costs
- No patient administration costs

Survey: Time-and-Motion Analysis

Analysis Description
- Stopwatch study of at least 10 infusion production occurrences
- Pharmacist/Technician activities to produce chemotherapy and supportive agents
- Describes details of clinical and cognitive activities related to oncology pharmacy services

Major Components
- Therapy Evaluation
  - Professional Consultation
  - Patient Care
  - Order Entry/Compounding
- Production/Evaluation

National Projection Results

<table>
<thead>
<tr>
<th>Infusion Preparation Costs for Medicare Patients Receiving Chemotherapy</th>
<th>Patients</th>
<th>Infusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total *</td>
<td>427,605</td>
<td>2,651,824</td>
</tr>
<tr>
<td>Proportion of Chemotherapy Infusions from Top 15 Agents</td>
<td>0.66</td>
<td></td>
</tr>
<tr>
<td>Projected Medicare Chemotherapy Infusions</td>
<td></td>
<td>3,990,495</td>
</tr>
<tr>
<td>Number of Infusions X Calculated Cost/Infusion from Current Study</td>
<td>$36.03</td>
<td>$143,777,535</td>
</tr>
</tbody>
</table>

* MedStat Marketscan® Medicare and COB Database
Summary

• Due to increased healthcare spending, reimbursement decisions for new health technology have become more rigorous.
• Decision making on reimbursement now more commonly considers the principles of health economics and outcomes research.
• The PORC conducts outcomes research to develop the evidence used in health care decision to public and private payers involved in allocating resources for new technologies.

References

• AMCP Concepts in Managed Care Pharmacy: Outcomes Research Slide deck at www.amcp.org.
• Outcomes Research Fact Sheet, Agency for Healthcare Research and Quality at http://www.ahrq.gov/clinic/outfact.htm